Jianzhong Xiao

Jianzhong Xiao


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
XWXiaojing Wang
Xiaojing Wang
QGQinli Guo
Qinli Guo
ZLZhaoxiang Liu
Zhaoxiang Liu
YWYanlei Wang
Yanlei Wang
CCChenxiang Cao
Chenxiang Cao
WZWenhui Zhao
Wenhui Zhao
Purpose: Obesity has become a major public health concern worldwide, increasing the risk of T2DM. Growing evidence indicates gut microbiota dysbiosis is related to metabolic disorders. We aimed to firstly investigate the compositional and functional features of the gut microbiome between obesity with and without T2DM in the Chinese population. Methods: A total of 32 obese individuals accompanied with T2DM and 18 age and gender-matched obesity with normal glucose tolerance (NGT) were enrolled. Fecal samples were collected, and the gut microbiota profile was determined using the Illumina MiSeq platform based on V3-V4 bacterial 16S rRNA gene. Results: Compared with obesity- NGT, obesity-T2DM showed a significantly higher alpha diversity. Principal coordinates analysis based on both Bray-Curtis distance and weighted Unifrac revealed that the global microbial composition was significantly different between the two groups (P = 0.007 and P = 0.005, respectively). At the phylum level, Obesity-T2DM patients exhibited a significant decrease in Bacteroidetes, and a pronounced increase in Firmicutes. Regarding the genus level, Bacteroides and Escherichia-Shigella were found to increase considerably, while Prevotella_9 and Sutterella had an evident decrease in Obesity-T2DM. Furthermore, Spearman correlation analysis revealed that Prevotella_9 and Sutterella were negatively associated with HbA1c and fasting blood glucose. Conclusion: We found clear differences in the gut microbiota composition in obesity-T2DM compared with obesity-NGT. Obesity accompanied with T2DM may aggravate the obesity-associated gut microbiota, and gut microbiota is expected to be a promising novel intervention target for obese management. However, larger sample size and more in-depth taxonomic identification studies are warranted.

9 March 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
ZLZhaoxiang Liu
Zhaoxiang Liu
XLXianglan Li
Xianglan Li
YWYanlei Wang
Yanlei Wang
YSYanxia Song
Yanxia Song
QLQiang Liu
Qiang Liu
JXJianzhong Xiao
Jianzhong Xiao
Introduction: Diabetic kidney disease (DKD) and diabetic retinopathy (DR) share similar pathophysiological mechanisms. However, signs of DKD may be present at diagnosis of diabetes without retinopathy. Risk factors for the development of DKD and DR may not be identical.Methods: This study aimed to evaluate the concordance and discordance between DKD and DR by investigating the distribution of DKD and DR in patients with type 2 diabetes mellitus from 5 Chinese cities. A total of 26,809 patients were involved in this study. The clinical characteristics were compared among patients based on the presence of DKD and DR. Logistic regression models were used to analyze the independent risk factors of DKD and DR.Results: The prevalence of DKD and DR was 32.3% and 34.6%, respectively. Among eligible patients, 1,752 patients without DR had an increased urinary albumin-to-creatinine ratio (ACR) or reduced estimated glomerular filtration rate (eGFR), and 1,483 patients with DR had no DKD. The positive predictive value of DR for DKD was 47.4% and negative predictive value was 67.1%. Elder age, male gender, a longer duration of disease, higher values of waist circumference and HbA1c were associated with both DR and DKD. A lower educational level was associated with DR. Higher BP and TG would predict increased prevalence of DKD.Conclusions: DKD and DR shared many risk factors, but a significant discordance was present in patients with type 2 diabetes mellitus. DKD was more strongly associated with blood pressure and triglycerides than DR.

31 March 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
ZLZhaoxiang Liu
Zhaoxiang Liu
LZLianhao Zhou
Lianhao Zhou
WZWenhui Zhao
Wenhui Zhao
LJLixia Jin
Lixia Jin
JZJinping Zhang
Jinping Zhang
JGJiandong Gao
Jiandong Gao
Purpose: This study investigates the incidence, predictors, and preventive strategies for microvascular complications in type 2 diabetes patients in community settings.Methods: Data were collected from 3,008 type 2 diabetes patients enrolled across 31 clinics in Beijing and Hebei. Prevalence and incidence of diabetic kidney disease (DKD), diabetic retinopathy (DR), and diabetic peripheral neuropathy (DPN) were assessed. Predictors were identified using XGBoost and Cox regression, and the impact of lifestyle and multifactorial interventions (MFI) was analyzed.Results: The prevalence of DKD, DR, and DPN were 39.5%, 26.2%, and 27.1%, respectively, with incidences of 74, 21, and 28 per 1000-person year. XGBoost identified that diabetes duration, age, HbA1c, FBG, triglyceride, BP, serum creatinine, proteinuria, aspirin and statin use were associated with those microvascular complications. The risk of DKD increased more rapidly as HbA1c exceeded 7.5% and decreased as blood pressure was maintained below 120/70 mmHg. Cox regression models showed that community-based intervention, including lifestyle modifications, were associated with a lower risk of DR and DPN. The study also found that higher variability in HbA1c and albumin-to-creatinine ratio (ACR) was associated with an increased risk of microvascular complications.Conclusions: Community-based interventions significantly reduce the of DR and DPN, highlighting the need for individualized glycemic and BP management in primary care. The findings emphasize the importance of comprehensive management strategies to prevent the development and progression of microvascular complications in type 2 diabetes patients.Clinical trial registration: http://www.chictr.org.cn/, identifier ChiCTR-TRC-13003222.

30 July 2021 in Medicine
Verified
Journal Article
Open access
LALingwang An
Lingwang An
YWYanlei Wang
Yanlei Wang
CCChenxiang Cao
Chenxiang Cao
TCTao Chen
Tao Chen
YZYonghong Zhang
Yonghong Zhang
JXJianzhong Xiao
Jianzhong Xiao
To evaluate the atherosclerotic cardiovascular diseases (ASCVD) risk factors in type 2 diabetes patients from the primary diabetes clinics for further comprehensive intervention in China. A cross-sectional study was conducted in 5 primary diabetes chain hospitals in Beijing, Lanzhou, Harbin, Chengdu, and Taiyuan in continuous patients with type 2 diabetes from March 2016 to December 2019. The data collected at the first visit were analyzed, and proportions of patients reached the targets (glycosylated hemoglobin [HbA1c] < 7%, blood pressure < 130/80 mm Hg, and low-density lipoprotein cholesterol [LDL-C] < 2.6mmol/l) were calculated. The clinical characteristics and the associated factors with achievement in HbA1c, blood pressure, and LDL-C targets were analyzed. A total of 20,412 participants, including 11,353 men (55.6%), with an average age of (59.4 ± 10.4) years were enrolled. Nearly 95% diabetes had one or more ASCVD risk factors other than hyperglycemia. The control rates of HbA1c, blood pressure, and LDL-C were 26.5%, 27.8%, and 42.6%, respectively. Only 4.1% patients achieved all 3 targets. Nearly 95% patients had one or more ASCVD risk factors other than hyperglyciemia. Diabetes duration, family history, and overweight/obesity were associated with the number of aggregated ASCVD risk factors. The patients with older age, no overweight/obesity, not smoking, less ASCVD risk factors, and having special diabetes care insurance (Chengdu) were associated with a higher control rates. To deal with poor control status, global management of ASCVD risk factors, weight loss, and smoking cessation must be emphasized in the primary diabetes care settings. Special diabetes care insurance should be advocated. Current ClinicalTrial.gov protocol ID NCT03707379. Date of Registration: October 16, 2018. https://clinicaltrials.gov.

13 December 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
ZLZhaoxiang Liu
Zhaoxiang Liu
WZWenhui Zhao
Wenhui Zhao
CCChenxiang Cao
Chenxiang Cao
YWYanlei Wang
Yanlei Wang
LXLuqi Xiao
Luqi Xiao
JXJianzhong Xiao
Jianzhong Xiao
Background: Pituitary stalk interruption syndrome (PSIS) is a congenital disease commonly found in patients with combined pituitary hormone deficiency (CPHD). Most PSIS patients manifest growth retardation and delayed puberty. We report a rare case of PSIS with tall stature, liver cirrhosis and diabetes, possibly caused by an inactivating KCNJ11 gene mutation.Case presentation: A 37-year-old female patient initially presented with liver cirrhosis and diabetes, without any secondary sexual characteristics. Endocrine investigation indicated CPHD. Small anterior pituitary, invisible pituitary stalk and no eutopic posterior lobe hypersignal in the sella turcica viewed in magnetic resonance imaging (MRI) confirmed the diagnosis of PSIS. Despite receiving no growth hormone or sex hormone therapy, she reached a final height of 186 cm. Liver histopathology revealed nonalcoholic fatty cirrhosis. Genetic testing identified a heterozygous p.Arg301Cys mutation in the KCNJ11 gene.Conclusion: This is a rare case of PSIS with liver cirrhosis and diabetes associated with an inactivating KCNJ11 gene mutation. It’s supposed that early hyperinsulinism caused by the KCNJ11 gene mutation, as well as delayed epiphyseal closure due to estrogen deficiency, contributed to the patient’s exceptionally tall stature. Untreated growth hormone deficiency (GHD) resulted in increased visceral fat, leading to nonalcoholic fatty liver disease (NAFLD) and cirrhosis. The decline in β cell function with age, combined with NAFLD, may have played a role in the development of diabetes.

21 August 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
JXJianzhong Xiao
Jianzhong Xiao
Since the establishment of the causal relationship between blood glucose levels and diabetes complications, glycemic control has become a cornerstone of diabetes metabolic management (1). In recent years, continuous glucose monitoring (CGM) systems have emerged as transformative tools for diabetes care (2). By measuring glucose levels in interstitial fluid, CGMs provide near-continuous real-time glucose readings and comprehensive ambulatory glucose profiles (AGP) (3). These capabilities are critical for optimizing insulin dosing, dietary planning, and physical activity management (4)(5)(6). The real-time visualization of glycemic variability has not only revolutionized diabetes treatment but also significantly enhanced patients' quality of life (7). Moreover, CGM-derived metrics such as Time in Range (TIR), Time Below Range (TBR), and Time Above Range (TAR) have introduced new paradigms in glycemic assessment (3). Notably, the application of CGM is expanding beyond traditional diabetes management, opening new frontiers in personalized health optimization. This article reviews current evidence including articles in this research topics, to discuss the potential applications, limitations, and prospects of CGM technology. Beyond Diabetes Management: Expanding Applications of CGM We know that glucose is a major substrate of energy metabolism and a core player in overall metabolic health, energy regulation, and cellular function. Fluctuations, even within physiologically "normal" ranges -can profoundly influence wellbeing and performance (8). This understanding has driven growing interest in CGM applications among non-diabetic populations: 1.Optimize metabolic health & prevent diabetes: CGM provides immediate, personalized feedback on how specific foods and dietary components (carbohydrate type/fiber/fat/protein ratio, serving size, order) affect blood glucose (9). One person's "healthy" meal can cause another person's blood sugar to spike dramatically (10). CGM provides support for truly personalized dietary choices to minimize harmful blood sugar spikes and promote metabolic stability. 2.Early identification and prevention of dysglycemia: CGM can reveal abnormal blood glucose fluctuations long before standard fasting blood glucose or HbA1c tests show abnormalities (11). Users seeing frequent or prolonged postprandial spikes can be a powerful motivator for lifestyle interventions to prevent the progression to type 2 diabetes (12). The "calorie intake, calorie burn" model is increasingly seen as oversimplifying. A spike in blood sugar triggers the release of insulin, a hormone that promotes fat storage and can inhibit fat burning (14). To identify foods that cause significant spikes and to choose dietary variety(i.e. low carbohydrate high protein) promoting more stable glucose and insulin levels, potentially create a more favorable hormonal environment for fat loss and muscle gain (15). Furthermore, large blood glucose spikes are often accompanied by rapid drops, which can trigger hunger, fatigue, and cravings -especially for more carbohydrates or sugar (16). Minimizing these spikes through dietary modification probably supports adherence to healthy eating patterns. 5.Understand energy, mood, and nerve function: Many people with diabetes experience depression. CGM can directly link these subjective feelings to blood sugar levels (17). Minimizing extreme blood sugar fluctuations by taking a CGM may help some people improve the nerve response to hypoglycemia (18). 6.Women's Health and Hormonal Fluctuations: Hormones such as estrogen and progesterone significantly affect insulin sensitivity. In most of the study population, glucose levels rose linearly throughout the menstrual cycle, reaching a maximum in the late luteal phase. A sharp decrease was seen in women at the beginning of menstrual bleeding (19). Polycystic ovary syndrome (PCOS) is often associated with insulin resistance. CGM can be a valuable tool for managing blood glucose levels in women with PCOS. 7.Longevity and diets intervention: Some researchers hypothesize that minimizing high blood sugar spikes and excessive variability (even within normal limits) may reduce oxidative stress and inflammation, potentially slowing the aging process (20). CGM provides data to proactively manage this variability. Biohackers used CGM to test the effects of various interventions-specific diets (ketosis, intermittent fasting), supplements, sleep patterns, stress reduction techniques-on their blood glucose profile, seeking optimal metabolic function (21). 8.Enhancing Quality of Life in Special Diabetic Populations. Type 1 diabetes management faces unique challenges during Ramadan, where patients experience dawn phenomenon before Suhoor meals, post-Iftar hyperglycemia, and nocturnal hypoglycemia risks(https://doi.org/10.3389/fendo.2025.1399990). Similarly, pregnant women with diabetes endure significant psychological burdens from stringent glycemic targets. Liu and collegues found CGM improved self-rating anxiety, pregnancy-related anxiety, and diabetes specific quality of life(https://doi.org/10.3389/fendo.2025.1470473). While advanced technologies like sensor-augmented pumps with automated insulin suspension theoretically alleviate hypoglycemia fear syndrome (HFS), current evidence indicates limited improvement regardless of SmartGuard™ or CGM implementation-potentially due to insufficient usage duration( https://doi.org/10.3389/fendo.2024.1419502). Notably, CGM offers unique advantages for evaluating novel hypoglycemic agents through comprehensive pharmacodynamic profiling of glucose excursions, surpassing traditional spot-check measurements (https://doi.org/10.3389/fendo.2024.1372593).